Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363670 · ClinicalTrials.gov registry record · Phase 2
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
A Phase 2 study, sponsored by ARS Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT05363670: Completed Phase 2 study, sponsored by ARS Pharmaceuticals.
NCT05363670 is a Phase 2 study that has completed, run by ARS Pharmaceuticals. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363670, a Phase 2 study, has completed, sponsored by ARS Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Primary Outcome
Difference in forced expiratory volume in 1 second (FEV1) based on area under the curve (AUC)
Interventions
- DRUG Placebo
- DRUG ARS-1
- DRUG Albuterol MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2024-02-02 |
| Phase | Phase 2 |
What the finished NCT05363670 record still lists
NCT05363670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05363670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05363670 about?
NCT05363670 is a clinical study titled "Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma". ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
What is the current status of trial NCT05363670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-07-28. Estimated completion is 2024-02-02.
What interventions are being tested in trial NCT05363670?
The interventions under investigation include: Placebo (DRUG), ARS-1 (DRUG), Albuterol MDI (DRUG).
Who is sponsoring clinical trial NCT05363670?
This trial is sponsored by ARS Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05363670's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI